Filtered By:
Source: Heart Rhythm
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 406 results found since Jan 2013.
Percutaneous left atrial appendage closure improves left atrial mechanical function through Frank –Starling mechanism
Modifications in left atrial (LA) flow velocities after left atrial appendage (LAA) exclusion have been shown in animal and ex vivo models. In a substudy of PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation), an objective improvement in quality of life was observed after LAA closure.
Source: Heart Rhythm - February 6, 2017 Category: Cardiology Authors: Augustin Coisne, Rosario Pilato, Fran çois Brigadeau, Didier Klug, Christelle Marquie, Zouheir Souissi, Marjorie Richardson, Stéphanie Mouton, Anne-Sophie Polge, Patrizio Lancellotti, Dominique Lacroix, David Montaigne Source Type: research
EWOLUTION – The Next Evolution in Appendage Closure?
Oral anticoagulation (OAC) is a class I indication for patients with non-valvular atrial fibrillation (AF) and 2 or more risk factors for stroke.1 However, many patients with AF are ineligible for OAC due to prohibitive bleeding. Subsequently, as a result of the pivotal role of the left atrial appendage (LAA) in the formation of thrombi, an alternative strategy to OAC is occlusion of the LAA.2 The WATCHMAN device (Boston Scientific Corporation, Marlborough, Massachusetts) is the only FDA approved LAA occlusion product studied in the randomized control trials (RCT) (Table 1).
Source: Heart Rhythm - June 22, 2017 Category: Cardiology Authors: Muhammad R. Afzal, Emile G. Daoud Source Type: research
EWOLUTION —The next evolution in appendage closure?
Oral anticoagulation (OAC) is a class I indication for patients with nonvalvular atrial fibrillation (AF) and ≥2 risk factors for stroke.1 However, many patients with AF are ineligible for OAC because of prohibitive bleeding. Subsequently, as a result of the pivotal role of the left atrial appendage (LAA) in the formation of thrombi, an alternative strategy to OAC is occlusion of the LAA.2 The WATCHMAN de vice (Boston Scientific Corporation, Marlborough, MA) is the only US Food and Drug Administration (FDA)–approved LAA occlusion product that has been studied in randomized control trials (RCTs) (Table).
Source: Heart Rhythm - June 22, 2017 Category: Cardiology Authors: Muhammad R. Afzal, Emile G. Daoud Tags: Editorial Commentary Source Type: research
EP News: Basic and Translational
Atrial fibrillation affects more than 33 million people worldwide and increases the risk of stroke, heart failure, and death. Fourteen genetic loci have been associated with atrial fibrillation in European and Asian ancestry groups. To further define the genetic basis of atrial fibrillation, Christophersen et al (Nat Genet 2017;49:946, PMID 28416818) performed large-scale, transancestry meta-analyses of common and rare variant association studies. The genome-wide association studies included 17,931 individuals with atrial fibrillation and 115,142 referents; the exome-wide association studies and rare v ariant association...
Source: Heart Rhythm - August 23, 2017 Category: Cardiology Authors: Penelope A. Boyden Tags: EP News: Basic and Translational Source Type: research
Utility and Limitations of Long-Term Monitoring of Atrial Fibrillation Using an Implantable Loop Recorder
Atrial fibrillation (AF) is the most common cardiac arrhythmia diagnosed and treated in the world. The treatment of patients ’ symptoms as well as the prevention of stroke and heart failure is dependent on accurate detection and characterization of AF. A variety of electrocardiographic (ECG) monitoring techniques are being used for these purposes. However, these intermittent ECG monitoring techniques have been shown to under diagnose AF events, while having limited ability to characterize AF burden and density.
Source: Heart Rhythm - September 13, 2017 Category: Cardiology Authors: Randall Lee, Suneet Mittal Source Type: research
Atrial Fibrillation and Cognitive Decline —Another Piece for a Big Puzzle
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is increasing over time.1, 2 AF is associated with an increased risk of stroke,3 heart failure,4 and death.5-7 In recent years, evidence has emerged to indicate that AF is associated with another growing public health problem: cognitive impairment and dementia.8 Although the evidence is compelling, existing studies suffer from several limitations such as reliance on the Mini-Mental State Examination, cross-sectional design, and lack of attention to domain-specific changes.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: Lin Y. Chen, Win-Kuang Shen Source Type: research
Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: comparison between uninterrupted direct oral anticoagulants and warfarin administration
The effect of uninterrupted oral anticoagulant use in patients with chronic kidney disease (CKD) during catheter ablation for atrial fibrillation (AF) is not fully understood.
Source: Heart Rhythm - October 26, 2017 Category: Cardiology Authors: Satoshi Yanagisawa, Yasuya Inden, Aya Fujii, Monami Ando, Junya Funabiki, Yosuke Murase, Masaki Takenaka, Noriaki Otake, Yoshihiro Ikai, Yusuke Sakamoto, Rei Shibata, Toyoaki Murohara Source Type: research
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden
In patients with cardiac implanted electronic devices (CIEDs) detection of new atrial fibrillation (AF) is associated with an increased risk of stroke.
Source: Heart Rhythm - November 6, 2017 Category: Cardiology Authors: Giuseppe Boriani, Taya V. Glotzer, Paul D. Ziegler, Mirko De Melis, Lorenza Mangoni di S. Stefano, Milan Sepsi, Maurizio Landolina, Maurizio Lunati, Thorsten Lewalter, A. John Camm Source Type: research
Atrial fibrillation and cognitive decline: Another piece for a big puzzle
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is increasing over time.1,2 AF is associated with an increased risk of stroke,3 heart failure,4 and death.5 –7 In recent years, evidence has emerged to indicate that AF is associated with another growing public health problem: cognitive impairment and dementia.8 Although the evidence is compelling, existing studies suffer from several limitations, such as reliance on the Mini-Mental State Examination, c ross-sectional design, and lack of attention to domain-specific changes.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: Lin Y. Chen, Win-Kuang Shen Tags: Editorial Commentary Source Type: research
Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients treated with vitamin K antagonists: A review
Identifying patients who are likely to achieve and maintain a therapeutic INR when prescribed a vitamin K antagonist (VKA) for stroke prevention in atrial fibrillation (AF) and venous thromboembolism (VTE) is challenging. The SAMe-TT2R2 score was developed based on common clinical factors that can highlight patients who may be unable to achieve and maintain good anticoagulation control and for whom a ‘trial of warfarin’ would be inadvisable. This review summarises the main published prospective and retrospective studies that have validated the SAMe-TT2R2 score in AF and VTE patients treated with a VKA and how the SAMe-...
Source: Heart Rhythm - November 24, 2017 Category: Cardiology Authors: Hanis Zulkifly, Gregory Y.H. Lip, Deirdre A. Lane Source Type: research
Mining the electronic medical record in patients with atrial fibrillation
I found several interesting nuggets of information in the new atrial fibrillation (AF) and stroke analysis from Patel et al1 published in this issue of HeartRhythm, starting with their use of the electronic medical record (EMR) to ask clinical questions. Most of us have a love-hate relationship with our EMR, but the undeniable truth is that it is here to stay. As you invest another late evening or the weekend catchi ng up with your EMR, how often have you wondered whether you can put all this documentation to scientific use? Certainly this is a laudable goal, but, in real life, easier said than done.
Source: Heart Rhythm - February 19, 2018 Category: Cardiology Authors: Sumeet S. Chugh Tags: Editorial Commentary Source Type: research
Does CHA2DS2-VASc Score reliably predict atrial arrhythmias? Analysis of a nationwide database of Remote Monitoring data daily transmitted from Cardiac Implantable Electronic Devices
CHA2DS2-VASc is a validated score for predicting stroke in patients with atrial fibrillation (AF).
Source: Heart Rhythm - February 22, 2018 Category: Cardiology Authors: Giovanni Rovaris, Francesco Solimene, Antonio D ’Onofrio, Gabriele Zanotto, Renato P. Ricci, Tiziana Mazzella, Saverio Iacopino, Paolo Della Bella, Giampiero Maglia, Gaetano Senatore, Fabio Quartieri, Mauro Biffi, Antonio Curnis, Valeria Calvi, Antonio Source Type: research
Is A Little Atrial Fibrillation Still Too Much?
Atrial fibrillation (AF) is most often viewed as a dichotomous variable, one that is either entirely present or absent. Guidelines support this perspective by recommending anticoagulation based on underlying stroke risk without regard to AF “type”, duration, or burden.1 The use of cardiac monitoring, however, has allowed us to quantify AF and associate outcomes with various arrhythmia characteristics.2, 3 These types of studies have raised legitimate doubts as to whether the 30 second threshold used to define AF is associated with meaningful consequences and have created equipoise for sub-clinical AF episodes lasting minutes to hours.
Source: Heart Rhythm - February 24, 2018 Category: Cardiology Authors: Rod Passman Source Type: research
Does the CHA2DS2-VASc score reliably predict atrial arrhythmias? Analysis of a nationwide database of remote monitoring data transmitted daily from cardiac implantable electronic devices
CHA2DS2-VASc is a validated score for predicting stroke in patients with atrial fibrillation (AF).
Source: Heart Rhythm - February 22, 2018 Category: Cardiology Authors: Giovanni Rovaris, Francesco Solimene, Antonio D'Onofrio, Gabriele Zanotto, Renato P. Ricci, Tiziana Mazzella, Saverio Iacopino, Paolo Della Bella, Giampiero Maglia, Gaetano Senatore, Fabio Quartieri, Mauro Biffi, Antonio Curnis, Valeria Calvi, Antonio Rap Source Type: research
Is a little atrial fibrillation still too much?
Atrial fibrillation (AF) is most often viewed as a dichotomous variable, one that is either entirely present or absent. Guidelines support this perspective by recommending anticoagulation based on underlying stroke risk without regard to AF “type,” duration, or burden.1 The use of cardiac monitoring, however, has allowed us to quantify AF and associate outcomes with various arrhythmia characteristics.2,3 These types of studies have raised legitimate doubts as to whether the 30-second threshold used to define AF is associated with m eaningful consequences and have created equipoise for subclinical AF episodes lasting minutes to hours.
Source: Heart Rhythm - February 24, 2018 Category: Cardiology Authors: Rod Passman Tags: Editorial Commentary Source Type: research
